Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 75 entries
Sorted by: Best Match Show Resources per page
[.

Frontiers in aging neuroscience

Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, Sauerbeck J, Rohrer G, Zach C, Vettermann F, Lang AE, Golbe L, Nübling G, Bartenstein P, Furukawa K, Ishiki A, Bötzel K, Danek A, Okamura N, Levin J, Rominger A.
PMID: 29387005
Front Aging Neurosci. 2018 Jan 17;9:440. doi: 10.3389/fnagi.2017.00440. eCollection 2017.

Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder characterized by deposition of fibrillar aggregates of 4R tau-protein in neurons and glial cells of the brain. These deposits are a key neuropathological finding, allowing a diagnosis of "definite PSP,"...

Cite
Brendel M, Schönecker S, Höglinger G, et al. [. Front Aging Neurosci. 2018;9:440doi: 10.3389/fnagi.2017.00440.
Brendel, M., Schönecker, S., Höglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J., Rohrer, G., Zach, C., Vettermann, F., Lang, A. E., Golbe, L., Nübling, G., Bartenstein, P., Furukawa, K., Ishiki, A., Bötzel, K., Danek, A., Okamura, N., Levin, J., & Rominger, A. (2017). [. Frontiers in aging neuroscience, 9440. https://doi.org/10.3389/fnagi.2017.00440
Brendel, Matthias, et al. "[." Frontiers in aging neuroscience vol. 9 (2017): 440. doi: https://doi.org/10.3389/fnagi.2017.00440
Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, Sauerbeck J, Rohrer G, Zach C, Vettermann F, Lang AE, Golbe L, Nübling G, Bartenstein P, Furukawa K, Ishiki A, Bötzel K, Danek A, Okamura N, Levin J, Rominger A. [. Front Aging Neurosci. 2018 Jan 17;9:440. doi: 10.3389/fnagi.2017.00440. eCollection 2017. PMID: 29387005; PMCID: PMC5776329.
Copy Download .nbib Format: NLM
Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson's Disease.

Brain sciences

Klietz M, Drexel SC, Schnur T, Lange F, Groh A, Paracka L, Greten S, Dressler D, Höglinger GU, Wegner F.
PMID: 32093188
Brain Sci. 2020 Feb 20;10(2). doi: 10.3390/brainsci10020111.

Parkinson's disease (PD) is a neurodegenerative movement disorder with progressive impairments in activities of daily living. With disease progression, people with PD (PwP) need more help and care from their spouses or professional caregivers. Identifying factors that help caregivers...

Cite
Klietz M, Drexel SC, Schnur T, et al. Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson's Disease. Brain Sci. 2020;10(2)doi: 10.3390/brainsci10020111.
Klietz, M., Drexel, S. C., Schnur, T., Lange, F., Groh, A., Paracka, L., Greten, S., Dressler, D., Höglinger, G. U., & Wegner, F. (2020). Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson's Disease. Brain sciences, 10(2), . https://doi.org/10.3390/brainsci10020111
Klietz, Martin, et al. "Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson's Disease." Brain sciences vol. 10,2 (2020). doi: https://doi.org/10.3390/brainsci10020111
Klietz M, Drexel SC, Schnur T, Lange F, Groh A, Paracka L, Greten S, Dressler D, Höglinger GU, Wegner F. Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson's Disease. Brain Sci. 2020 Feb 20;10(2). doi: 10.3390/brainsci10020111. PMID: 32093188; PMCID: PMC7071391.
Copy Download .nbib Format: NLM
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

Alzheimer's & dementia (Amsterdam, Netherlands)

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.
PMID: 30984816
Alzheimers Dement (Amst). 2019 Apr 02;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

INTRODUCTION: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying...

Cite
van Eimeren T, Antonini A, Berg D, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019;11:301-309doi: 10.1016/j.dadm.2019.01.011.
van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M. C., Piccini, P., Pineda-Pardo, J. �. �., Rektorová, I., Rodríguez-Oroz, M., Rominger, A., Seppi, K., Stoessl, A. J., Tessitore, A., Thobois, S., Kaasinen, V., Wenning, G., Siebner, H. R., Strafella, A. P., & Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's & dementia (Amsterdam, Netherlands), 11301-309. https://doi.org/10.1016/j.dadm.2019.01.011
van Eimeren, Thilo, et al. "Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 11 (2019): 301-309. doi: https://doi.org/10.1016/j.dadm.2019.01.011
van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019 Apr 02;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec. PMID: 30984816; PMCID: PMC6446052.
Copy Download .nbib Format: NLM
Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.

Frontiers in neurology

Viscidi E, Litvan I, Dam T, Juneja M, Li L, Krzywy H, Eaton S, Hall S, Kupferman J, Höglinger GU.
PMID: 34220661
Front Neurol. 2021 Jun 17;12:571800. doi: 10.3389/fneur.2021.571800. eCollection 2021.

No abstract available.

Cite
Viscidi E, Litvan I, Dam T, et al. Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Front Neurol. 2021;12:571800doi: 10.3389/fneur.2021.571800.
Viscidi, E., Litvan, I., Dam, T., Juneja, M., Li, L., Krzywy, H., Eaton, S., Hall, S., Kupferman, J., & Höglinger, G. U. (2021). Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Frontiers in neurology, 12571800. https://doi.org/10.3389/fneur.2021.571800
Viscidi, Emma, et al. "Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database." Frontiers in neurology vol. 12 (2021): 571800. doi: https://doi.org/10.3389/fneur.2021.571800
Viscidi E, Litvan I, Dam T, Juneja M, Li L, Krzywy H, Eaton S, Hall S, Kupferman J, Höglinger GU. Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Front Neurol. 2021 Jun 17;12:571800. doi: 10.3389/fneur.2021.571800. eCollection 2021. PMID: 34220661; PMCID: PMC8245849.
Copy Download .nbib Format: NLM
Differential expression of gut miRNAs in idiopathic Parkinson's disease.

Parkinsonism & related disorders

Kurz A, Kumar R, Northoff BH, Wenk C, Schirra J, Donakonda S, Höglinger GU, Schwarz J, Rozanski V, Hübner R, Bötzel K, Holdt LM, Koeglsperger T.
PMID: 34118643
Parkinsonism Relat Disord. 2021 Jul;88:46-50. doi: 10.1016/j.parkreldis.2021.05.022. Epub 2021 Jun 01.

OBJECTIVE: In the present work, we aimed to investigate the expression of microRNAs (miRNAs) in routine colonic biopsies obtained from patients with idiopathic Parkinson's disease (PD) and to address their value as a diagnostic biomarker for PD and their...

Cite
Kurz A, Kumar R, Northoff BH, et al. Differential expression of gut miRNAs in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2021;88:46-50doi: 10.1016/j.parkreldis.2021.05.022.
Kurz, A., Kumar, R., Northoff, B. H., Wenk, C., Schirra, J., Donakonda, S., Höglinger, G. U., Schwarz, J., Rozanski, V., Hübner, R., Bötzel, K., Holdt, L. M., & Koeglsperger, T. (2021). Differential expression of gut miRNAs in idiopathic Parkinson's disease. Parkinsonism & related disorders, 8846-50. https://doi.org/10.1016/j.parkreldis.2021.05.022
Kurz, Anna, et al. "Differential expression of gut miRNAs in idiopathic Parkinson's disease." Parkinsonism & related disorders vol. 88 (2021): 46-50. doi: https://doi.org/10.1016/j.parkreldis.2021.05.022
Kurz A, Kumar R, Northoff BH, Wenk C, Schirra J, Donakonda S, Höglinger GU, Schwarz J, Rozanski V, Hübner R, Bötzel K, Holdt LM, Koeglsperger T. Differential expression of gut miRNAs in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2021 Jul;88:46-50. doi: 10.1016/j.parkreldis.2021.05.022. Epub 2021 Jun 01. PMID: 34118643.
Copy Download .nbib Format: NLM
Role of Benzoic Acid and Lettucenin A in the Defense Response of Lettuce against Soil-Borne Pathogens.

Plants (Basel, Switzerland)

Windisch S, Walter A, Moradtalab N, Walker F, Höglinger B, El-Hasan A, Ludewig U, Neumann G, Grosch R.
PMID: 34834699
Plants (Basel). 2021 Oct 29;10(11). doi: 10.3390/plants10112336.

Soil-borne pathogens can severely limit plant productivity. Induced defense responses are plant strategies to counteract pathogen-related damage and yield loss. In this study, we hypothesized that benzoic acid and lettucenin A are involved as defense compounds against

Cite
Windisch S, Walter A, Moradtalab N, et al. Role of Benzoic Acid and Lettucenin A in the Defense Response of Lettuce against Soil-Borne Pathogens. Plants (Basel). 2021;10(11)doi: 10.3390/plants10112336.
Windisch, S., Walter, A., Moradtalab, N., Walker, F., Höglinger, B., El-Hasan, A., Ludewig, U., Neumann, G., & Grosch, R. (2021). Role of Benzoic Acid and Lettucenin A in the Defense Response of Lettuce against Soil-Borne Pathogens. Plants (Basel, Switzerland), 10(11), . https://doi.org/10.3390/plants10112336
Windisch, Saskia, et al. "Role of Benzoic Acid and Lettucenin A in the Defense Response of Lettuce against Soil-Borne Pathogens." Plants (Basel, Switzerland) vol. 10,11 (2021). doi: https://doi.org/10.3390/plants10112336
Windisch S, Walter A, Moradtalab N, Walker F, Höglinger B, El-Hasan A, Ludewig U, Neumann G, Grosch R. Role of Benzoic Acid and Lettucenin A in the Defense Response of Lettuce against Soil-Borne Pathogens. Plants (Basel). 2021 Oct 29;10(11). doi: 10.3390/plants10112336. PMID: 34834699; PMCID: PMC8618419.
Copy Download .nbib Format: NLM
Relationship Satisfaction in People with Parkinson's Disease and Their Caregivers: A Cross-Sectional Observational Study.

Brain sciences

Heine J, von Eichel H, Staege S, Höglinger GU, Wegner F, Klietz M.
PMID: 34205764
Brain Sci. 2021 Jun 21;11(6). doi: 10.3390/brainsci11060822.

Parkinson's disease (PD) is a neurodegenerative disorder, which leads to reduced health-related quality of life (HR-QoL) and autonomy in advanced stages of the disease. Hence, people with PD (PwPD) are in need of help, which is often provided by...

Cite
Heine J, von Eichel H, Staege S, et al. Relationship Satisfaction in People with Parkinson's Disease and Their Caregivers: A Cross-Sectional Observational Study. Brain Sci. 2021;11(6)doi: 10.3390/brainsci11060822.
Heine, J., von Eichel, H., Staege, S., Höglinger, G. U., Wegner, F., & Klietz, M. (2021). Relationship Satisfaction in People with Parkinson's Disease and Their Caregivers: A Cross-Sectional Observational Study. Brain sciences, 11(6), . https://doi.org/10.3390/brainsci11060822
Heine, Johanne, et al. "Relationship Satisfaction in People with Parkinson's Disease and Their Caregivers: A Cross-Sectional Observational Study." Brain sciences vol. 11,6 (2021). doi: https://doi.org/10.3390/brainsci11060822
Heine J, von Eichel H, Staege S, Höglinger GU, Wegner F, Klietz M. Relationship Satisfaction in People with Parkinson's Disease and Their Caregivers: A Cross-Sectional Observational Study. Brain Sci. 2021 Jun 21;11(6). doi: 10.3390/brainsci11060822. PMID: 34205764; PMCID: PMC8234945.
Copy Download .nbib Format: NLM
SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population.

Frontiers in medicine

Ladage D, Höglinger Y, Ladage D, Adler C, Yalcin I, Harzer O, Braun RJ.
PMID: 34109189
Front Med (Lausanne). 2021 May 24;8:632942. doi: 10.3389/fmed.2021.632942. eCollection 2021.

No abstract available.

Cite
Ladage D, Höglinger Y, Ladage D, et al. SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population. Front Med (Lausanne). 2021;8:632942doi: 10.3389/fmed.2021.632942.
Ladage, D., Höglinger, Y., Ladage, D., Adler, C., Yalcin, I., Harzer, O., & Braun, R. J. (2021). SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population. Frontiers in medicine, 8632942. https://doi.org/10.3389/fmed.2021.632942
Ladage, Dennis, et al. "SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population." Frontiers in medicine vol. 8 (2021): 632942. doi: https://doi.org/10.3389/fmed.2021.632942
Ladage D, Höglinger Y, Ladage D, Adler C, Yalcin I, Harzer O, Braun RJ. SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population. Front Med (Lausanne). 2021 May 24;8:632942. doi: 10.3389/fmed.2021.632942. eCollection 2021. PMID: 34109189; PMCID: PMC8180586.
Copy Download .nbib Format: NLM
Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy.

Frontiers in neurology

Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Höglinger GU.
PMID: 33967937
Front Neurol. 2021 Apr 22;12:637176. doi: 10.3389/fneur.2021.637176. eCollection 2021.

No abstract available.

Cite
Kwasny MJ, Oleske DM, Zamudio J, et al. Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy. Front Neurol. 2021;12:637176doi: 10.3389/fneur.2021.637176.
Kwasny, M. J., Oleske, D. M., Zamudio, J., Diegidio, R., & Höglinger, G. U. (2021). Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy. Frontiers in neurology, 12637176. https://doi.org/10.3389/fneur.2021.637176
Kwasny, Mary J, et al. "Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy." Frontiers in neurology vol. 12 (2021): 637176. doi: https://doi.org/10.3389/fneur.2021.637176
Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Höglinger GU. Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy. Front Neurol. 2021 Apr 22;12:637176. doi: 10.3389/fneur.2021.637176. eCollection 2021. PMID: 33967937; PMCID: PMC8100604.
Copy Download .nbib Format: NLM
Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?.

Brain sciences

Krey L, Huber MK, Höglinger GU, Wegner F.
PMID: 34942956
Brain Sci. 2021 Dec 18;11(12). doi: 10.3390/brainsci11121654.

The SARS-CoV-2 pandemic has affected the daily life of the worldwide population since 2020. Links between the newly discovered viral infection and the pathogenesis of neurodegenerative diseases have been investigated in different studies. This review aims to summarize the...

Cite
Krey L, Huber MK, Höglinger GU, et al. Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?. Brain Sci. 2021;11(12)doi: 10.3390/brainsci11121654.
Krey, L., Huber, M. K., Höglinger, G. U., & Wegner, F. (2021). Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?. Brain sciences, 11(12), . https://doi.org/10.3390/brainsci11121654
Krey, Lea, et al. "Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?." Brain sciences vol. 11,12 (2021). doi: https://doi.org/10.3390/brainsci11121654
Krey L, Huber MK, Höglinger GU, Wegner F. Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?. Brain Sci. 2021 Dec 18;11(12). doi: 10.3390/brainsci11121654. PMID: 34942956.
Copy Download .nbib Format: NLM
Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion.

Cell death & disease

Tang Q, Gao P, Arzberger T, Höllerhage M, Herms J, Höglinger G, Koeglsperger T.
PMID: 34535638
Cell Death Dis. 2021 Sep 17;12(10):854. doi: 10.1038/s41419-021-04138-0.

Dopaminergic (DA) cell death in Parkinson's disease (PD) is associated with the gradual appearance of neuronal protein aggregates termed Lewy bodies (LBs) that are comprised of vesicular membrane structures and dysmorphic organelles in conjunction with the protein alpha-Synuclein (α-Syn)....

Cite
Tang Q, Gao P, Arzberger T, et al. Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion. Cell Death Dis. 2021;12(10):854doi: 10.1038/s41419-021-04138-0.
Tang, Q., Gao, P., Arzberger, T., Höllerhage, M., Herms, J., Höglinger, G., & Koeglsperger, T. (2021). Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion. Cell death & disease, 12(10), 854. https://doi.org/10.1038/s41419-021-04138-0
Tang, Qilin, et al. "Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion." Cell death & disease vol. 12,10 (2021): 854. doi: https://doi.org/10.1038/s41419-021-04138-0
Tang Q, Gao P, Arzberger T, Höllerhage M, Herms J, Höglinger G, Koeglsperger T. Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion. Cell Death Dis. 2021 Sep 17;12(10):854. doi: 10.1038/s41419-021-04138-0. PMID: 34535638; PMCID: PMC8448865.
Copy Download .nbib Format: NLM
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.

Journal of Parkinson's disease

Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ.
PMID: 34897099
J Parkinsons Dis. 2021 Dec 10; doi: 10.3233/JPD-212714. Epub 2021 Dec 10.

BACKGROUND: Glucocerebrosidase gene (GBA) mutations influence risk and prognosis of Parkinson's disease (PD), possibly through accumulation of glycosphingolipids, including glucosylceramide (GL-1). Venglustat is a novel, brain penetrant glucosylceramide synthase inhibitor.OBJECTIVE: Evaluate venglustat pharmacology, safety, and tolerability in patients with...

Cite
Peterschmitt MJ, Saiki H, Hatano T, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis. 2021;doi: 10.3233/JPD-212714.
Peterschmitt, M. J., Saiki, H., Hatano, T., Gasser, T., Isaacson, S. H., Gaemers, S. J. M., Minini, P., Saubadu, S., Sharma, J., Walbillic, S., Alcalay, R. N., Cutter, G., Hattori, N., Höglinger, G. U., Marek, K., Schapira, A. H. V., Scherzer, C. R., Simuni, T., Giladi, N., Sardi, S. P., Fischer, T. Z. (2021). Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's disease, . https://doi.org/10.3233/JPD-212714
Peterschmitt, M Judith, et al. "Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial." Journal of Parkinson's disease vol. (2021). doi: https://doi.org/10.3233/JPD-212714
Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis. 2021 Dec 10; doi: 10.3233/JPD-212714. Epub 2021 Dec 10. PMID: 34897099.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 75 entries